The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.
Creatine may affect hair loss by reducing PGE2 levels, which could influence hair growth. The discussion highlights the need for more research on this potential mechanism.
Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.
The conversation discusses the potential benefits and risks of using Methionine and Glycine for hair loss, with concerns about cancer risk if not balanced properly. The user seeks opinions on these amino acids for hair health and overall benefits.
An increase in libido associated with the use of Pyri, and a discussion about how it may be working comparably to other hair loss treatments such as RU58841, Finasteride and Minoxidil.
The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.
The post discusses a new hair loss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.
The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.
Transitioning from finasteride to Pyrilutamide as a treatment for hair loss, and the potential risks associated with taking such a drug. People have discussed the need to wait at least 6 months in order to assess results, and are willing to risk their health trying this new medication.
RU58841 is preferred over finasteride for blocking DHT on the scalp, especially for those with aggressive MPB. Creatine is associated with increased hair shedding, even when using RU58841.
The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.
A user ingested RU58841 orally and experienced severe heart and breathing issues, requiring emergency medical assistance. They concluded that MV supplements is a legitimate supplier but warned of the serious side effects.
The conversation discusses skepticism over the results of Pyrilutamide for hair regrowth, suggesting that results from rigorous trials are more trustworthy. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
The launch of Pyrilutamide as a potential hair loss treatment, with people discussing whether it is better than treatments like finasteride and minoxidil. Some participants have also discussed the risks associated with importing drugs from China.
Actifollic selling Pyrilutamide as a treatment for hair loss, with people debating its efficacy compared to Minoxidil and Finasteride in combination with RU58841.
PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
The conversation discusses hair loss treatments, specifically mentioning pyrilutamide, minoxidil, and finasteride. The consensus suggests starting treatment early, with finasteride being a preferred option.
Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hair follicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.
The conversation is about finding a legitimate source for Procyanidin B2 or Apple Extract with a clear percentage of Procyanidin B2 for making a topical solution. The user reports thicker and darker body hair after taking Oral Apple Polyphenols extract.
Hair loss therapies focusing on hair follicle sugar metabolism and aldose reductase. Potential treatments include magnesium supplements, avoiding high glycemic index foods, and antioxidants.
GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.
The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.